Rapid and Sustained Relief from the Symptoms of Carcinoid Syndrome: Results from an Open 6-Month Study of the 28-Day Prolonged-Release Formulation of Lanreotide

Publisher： Karger

E-ISSN： 1423-0194|80|4|244-251

ISSN： 0028-3835

Source： Neuroendocrinology, Vol.80, Iss.4, 2005-01, pp. : 244-251

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Three-Month Sustained-Release Form of Triptorelin in Patients with Advanced Prostatic Adenocarcinoma: Results of an Open Pharmacodynamic and Pharmacokinetic Multicenter Study

By  

Hormone Research in Paediatrics, Vol. 50, Iss. 2, 1998-08 ,pp. : 89-93

Karger

Access to resources Recommend Favorite

Meta-Analysis of Paediatric Patients with Central Precocious Puberty Treated with Intramuscular Triptorelin 11.25 mg 3-Month Prolonged-Release Formulation


By  

Hormone Research in Paediatrics, Vol. 87, Iss. 4, 2017-03 ,pp. : 224-232

Karger

Access to resources Recommend Favorite

Pharmacodynamic Equivalence of a Decapeptyl 3-Month SR Formulation with the 28-Day SR Formulation in Patients with Advanced Prostate Cancer

By  

Hormone Research in Paediatrics, Vol. 62, Iss. 5, 2004-11 ,pp. : 252-258

Karger

Access to resources Recommend Favorite

Octreotide Exerts Only Acute, but No Sustained, Effects on MRI Enhancement of Liver Metastases in Carcinoid Syndrome

By  

Neuroendocrinology, Vol. 82, Iss. 1, 2006-01 ,pp. : 41-48

Karger

Access to resources Recommend Favorite

Interventional Treatment of the Carcinoid Syndrome

By  

Neuroendocrinology, Vol. 80, Iss. 1, 2004-10 ,pp. : 67-73

Karger

Access to resources Recommend Favorite